Vanguard Global Advisers »

Xilio Therapeutics shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Xilio Therapeutics shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Xilio Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Xilio Therapeutics held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Xilio Therapeutics by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.8k 210 8.41

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Xilio Therapeutics

Bain Capital Life Sciences Investors
Frazier Life Sciences Management
Vanguard Capital Management
Merck & Co
Morgan Stanley
AJU IB Investment
Geode Capital Management
Vanguard Fiduciary Trust
GSA Capital Partners
Ghisallo Capital Management
UBS Group
Vanguard Global Advisers
Royal Bank of Canada
Key FInancial

View all funds holding Xilio Therapeutics